PDCD1 and neoplasm: Recent data correlated clinical benefit of PD1/PD-L1 immune checkpoint inhibition with the expression level of membrane-associated PD-L1 on tumor cells, commonly induced by Interferon-γ (IFN-γ)-mediated signaling (3).